Diverse Investor Backing for Avation Medical:
In a recent funding round, Avation Medical successfully raised capital, with ShangBay Capital and Asahi Kasei leading the investment.
The round also saw participation from Angelini Ventures, JobsOhio Growth Capital Fund, Arboretum Ventures, Tonkawa, Medtronic, and Avestria Ventures.
This diverse group of investors underscores the broad appeal and potential of Avation Medical’s innovative offerings.
Funds Allocated for U.S. Launch of Vivally System:
The funds obtained through the financing round are earmarked for the upcoming U.S. launch of Avation Medical’s Vivally System.
With a strategic focus on making wearable peripheral neuromodulation accessible, the company aims to introduce a novel solution for patients dealing with various clinical conditions, particularly those affected by overactive bladder syndrome (OAB).
Overview of Vivally System:
Avation Medical, under the leadership of CEO Jill Schiaparelli, is at the forefront of neuromodulation and digital health.
The Vivally System, an FDA-cleared, closed-loop, at-home wearable neuromodulation device, is a key component of the company’s offerings.
When paired with a companion mobile application, Vivally provides a comprehensive therapy and support system.
It caters to patients dealing with urge urinary incontinence and urinary urgency resulting from OAB.
The device is prescribed following a brief clinical evaluation, including personalized calibration, which establishes specific parameters based on individual patient needs.
Upcoming U.S. Launch in Spring 2024:
Anticipating a highly awaited release, Avation Medical plans to launch the Vivally System in key U.S. markets in early Spring 2024.
With availability through prescription, the system aims to redefine standards in overactive bladder care, providing a non-invasive wearable neuromodulation therapy option.
CEO Jill Schiaparelli’s Perspective:
Jill Schiaparelli, CEO of Avation Medical, expressed gratitude for the new capital infusion, emphasizing its role in propelling the launch of Vivally.
She highlighted the company’s commitment to advancing non-invasive wearable neuromodulation therapy, emphasizing the potential benefits for both patients and clinicians.
Schiaparelli also acknowledged the strength of institutional support from investors as Avation Medical accelerates efforts to bring its innovative technology to the market.
In conclusion, Avation Medical’s successful funding round positions the company for a transformative U.S. launch of the Vivally System.
With a focus on accessibility and innovation in neuromodulation therapy, Avation Medical is poised to make a significant impact on the healthcare landscape.